DE60232282D1 - Modified factor VIII cDNA and its use for the production of factor VIII - Google Patents

Modified factor VIII cDNA and its use for the production of factor VIII

Info

Publication number
DE60232282D1
DE60232282D1 DE60232282T DE60232282T DE60232282D1 DE 60232282 D1 DE60232282 D1 DE 60232282D1 DE 60232282 T DE60232282 T DE 60232282T DE 60232282 T DE60232282 T DE 60232282T DE 60232282 D1 DE60232282 D1 DE 60232282D1
Authority
DE
Germany
Prior art keywords
factor viii
cdna
production
modified
factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60232282T
Other languages
German (de)
Inventor
Claude Negrier
Jean-Luc Plantier
Marie Helene Rodrigeuz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE60232282D1 publication Critical patent/DE60232282D1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A modified Factor VIII cDNA is disclosed wherein the B-domain of the wild type factor cDNA has been deleted and a truncated Factor IX intron 1 has been inserted in two locations of the Factor VIII cDNA and as a promoter a cDNA is used which is suitable for the expression in hematopoietic cell lines and specifically in platelets.
DE60232282T 2001-02-09 2002-01-22 Modified factor VIII cDNA and its use for the production of factor VIII Expired - Lifetime DE60232282D1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01102810A EP1233064A1 (en) 2001-02-09 2001-02-09 Modified factor VIII cDNA and its use for the production of factor VIII

Publications (1)

Publication Number Publication Date
DE60232282D1 true DE60232282D1 (en) 2009-06-25

Family

ID=8176417

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60232282T Expired - Lifetime DE60232282D1 (en) 2001-02-09 2002-01-22 Modified factor VIII cDNA and its use for the production of factor VIII

Country Status (8)

Country Link
US (1) US6780614B2 (en)
EP (1) EP1233064A1 (en)
JP (1) JP2002291472A (en)
KR (1) KR100899949B1 (en)
AT (1) ATE431363T1 (en)
AU (1) AU785354B2 (en)
CA (1) CA2371447A1 (en)
DE (1) DE60232282D1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2450125A1 (en) * 2001-06-15 2002-12-27 Andre C. Schuh Gene therapy for hemophilia a
SI1673391T1 (en) * 2003-10-16 2009-06-30 Claude Negrier MODIFIED cDNA FOR HIGH EXPRESSION LEVELS OF FACTOR VIII AND ITS DERIVATIVES
DE602004026474D1 (en) * 2003-12-03 2010-05-20 Univ Rochester RECOMBINANT FACTOR VIII WITH INCREASED SPECIFIC ACTIVITY
JPWO2007049749A1 (en) * 2005-10-28 2009-04-30 ディナベック株式会社 Treatment method for abnormal blood coagulation
FR2913020B1 (en) * 2007-02-23 2012-11-23 Biomethodes NEW VIII FACTORS FOR THE TREATMENT OF TYPE A HEMOPHILS
CA2703948A1 (en) * 2007-11-01 2009-05-07 University Of Rochester Recombinant factor viii having increased stability
US20110077202A1 (en) 2008-05-16 2011-03-31 Bayer Healthcare Llc Targeted Coagulation Factors and Method of Using the Same
BRPI1105317A2 (en) 2011-01-24 2013-04-30 Fundacco Hemoct De Ribeirco Preto stable and large-scale production of human fviii in human cell line sk-hep-1
EP3904376A1 (en) 2013-06-24 2021-11-03 Xiao, Weidong Mutant factor viii compositions and methods
KR20160138477A (en) * 2014-03-23 2016-12-05 어드밴텍 바이오사이언스 파마큐티카 엘티디에이 Enhancement of recombinant protein expression with copper
WO2015149143A2 (en) 2014-04-01 2015-10-08 Advantech Bioscience Farmacêutica Ltda. Stable factor viii formulations with low sugar-glycine
CN106456720A (en) 2014-04-01 2017-02-22 爱德技术生物科学有限公司 Stabilization of factor viii without calcium as an excipient
US11795207B2 (en) 2021-03-30 2023-10-24 AAVnerGene Inc. Modified plasma clotting factor VIII and method of use thereof
EP4314041A1 (en) 2021-03-30 2024-02-07 Aavnergene Inc. Modified plasma clotting factor viii and method of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8501050D0 (en) 1985-03-05 1985-03-05 Kabivitrum Ab BIOLOGICALLY ACTIVE FRAGMENTS OF HUMAN ANTIHEMOPHILIC FACTOR AND METHOD FOR PREPARATION THEREOF
KR910006424B1 (en) 1985-08-21 1991-08-24 인코텍스 비.브이 Method of manufacturing knitted briefs
DE3785102T2 (en) 1986-01-03 1993-07-22 Genetics Inst METHOD FOR PRODUCING FACTOR VIII: C TYPE PROTEINS.
DE3720246A1 (en) 1987-06-19 1988-12-29 Behringwerke Ag FACTOR VIII: C-LIKE MOLECULE WITH COAGULATION ACTIVITY
FR2619314B1 (en) 1987-08-11 1990-06-15 Transgene Sa FACTOR VIII ANALOG, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
SE468050C (en) * 1991-03-15 1998-04-27 Pharmacia & Upjohn Ab Recombinant human factor VIII derivative
FR2763959A1 (en) 1997-06-02 1998-12-04 Transgene Sa NOVEL RECOMBINANT ADENOVIRAL VECTORS INCLUDING A SPLICE SEQUENCE
EP1038959A1 (en) * 1999-03-17 2000-09-27 Aventis Behring Gesellschaft mit beschränkter Haftung Factor VIII without B-domain, comprising one or more insertions of a truncated intron I of factor IX
EP1048726B1 (en) * 1999-04-27 2006-07-26 Négrier, Claude Modified factor VIII cDNA
EP1231220B1 (en) 2001-02-09 2009-05-13 Claude Négrier Modified factor VIII cDNa and its use for the production of factor VIII

Also Published As

Publication number Publication date
ATE431363T1 (en) 2009-05-15
US20020182684A1 (en) 2002-12-05
CA2371447A1 (en) 2002-08-09
JP2002291472A (en) 2002-10-08
AU1555502A (en) 2002-08-15
EP1233064A1 (en) 2002-08-21
KR100899949B1 (en) 2009-05-28
AU785354B2 (en) 2007-02-01
KR20020066385A (en) 2002-08-16
US6780614B2 (en) 2004-08-24

Similar Documents

Publication Publication Date Title
DE60232282D1 (en) Modified factor VIII cDNA and its use for the production of factor VIII
ATE334199T1 (en) MODIFIED FACTOR VIII CDNA
DE69710104D1 (en) Binder solution based on vinylidene fluoride and composition for the production of electrodes
ATE56703T1 (en) SUBSTITUTED AZETIDINONES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE MANUFACTURE OF ANTI-INFLAMMATORY AND ANTIDEGENERATIVE MEDICATIONS.
DE60015082D1 (en) ARTIFICIAL PEPTIDES WITH SURFACE ACTIVITY AND THEIR USE FOR THE PRODUCTION OF ARTIFICIAL SURFACES
DE60133802D1 (en) USE OF ACID STABILES PROTEASES IN ANIMAL FEED
DE68928368D1 (en) Recombinant DNA, bacterium of the genus Pseudomonas containing it and its use for the production of lipase
ATE229334T1 (en) USE OF CRF ANTAGONISTS
DE60227718D1 (en) Use of 2-fuoro-3-ketoesters for the preparation of 3-fuoro-6,7,8,9-tetrahydro-4H-pyrimido-1,2-a-pyrimidin-4-ones
ATE202499T1 (en) CATALYST SUPPORT BASED ON TITANIUM OXIDE
DE60318026D1 (en) HYBRID HEPATOCYTE GROWTH FACTORS HAVING HIGH EXPRESSION EFFICIENCY OF TWO HEPATOCYTE GROWTH FACTOR HETEROTYPES
DK1077941T3 (en) Compounds with growth hormone releasing properties
DE3855449D1 (en) DNA clones from human thrombomodulin
DE60218807D1 (en) Ruthenium complexes and their use for the production of alcohols
DE60211632D1 (en) Use of Cyclotetrasaccharides to Increase the "Active-Oxygen Eliminating Activity"
ATE73462T1 (en) HIRUDIN VARIANT, ITS USE AND MANUFACTURE.
DE69711974D1 (en) Process for the purification of 2,6-dimethylnaphthol and its use in the production of 2,6-naphtholdicarboxylic acid
DE60239670D1 (en) USE OF OXYTOCIN FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION AGAINST CARCINOMA IN SITU AND ZERVIZITIS
DE69313316D1 (en) Use of oxazopyrroloquinolines and pyrroloquinolone quinones for the production of production accelerators of nerve growth factors g
ATE292686T1 (en) PRODUCTION OF NISIN VARIANTS
DE69812438T2 (en) COMPOSITION FOR THE PRODUCTION OF FUEL BRIKETTS
DE69929638D1 (en) Plasmids, their construction and use for the production of interleukin-4 and its muteins
DK1048726T3 (en) Modified factor VIII cDNA
DK0944612T3 (en) N- (4-acetyl-1-piperazinyl) -4-fluorbenzamidhydrat
DE69418938D1 (en) ADDITIVES FOR THE PRODUCTION OF ALLOYS

Legal Events

Date Code Title Description
8364 No opposition during term of opposition